Navigation Links
Stem Cell Transplantation Program at Hackensack University Medical Center: First in Nation to Receive Joint Commission Certification for Quality and First in New Jersey to be Named a Blue Distinction(R) Center for Specialty Care.
Date:10/2/2008

HACKENSACK, N.J., Oct. 2 /PRNewswire/ -- The Blood and Marrow Stem Cell Transplantation Program at the John Theurer Cancer Center at Hackensack University Medical Center is the first in the United States to receive Disease Specific Care Certification for stem cell transplantation from The Joint Commission, the nation's leading accrediting agency for hospitals and healthcare organizations. The Blood and Marrow Transplantation Program also recently became the first and only program in New Jersey to be named a Blue Distinction(R) Center for Specialty Care by the nationwide Blue Cross and Blue Shield companies.

Both of these designations attest to the high quality of the program's clinical services, the expertise of its faculty and staff, stringent quality indicators that are maintained, research studies that are under way, and a rigorous quest for continuous improvement. The Blood and Marrow Stem Cell Transplantation Program is one of the 10 largest in the United States. Nearly 300 adults and children throughout the country with cancer and serious blood disorders come to the John Theurer Cancer Center each year to undergo a life-saving stem cell transplant at the program. Last year, the program reported outcomes success rates of more than 95 percent for the procedure.

"These designations attest to the high level of expertise offered by our Blood and Marrow Stem Cell Transplantation Program's chief, Dr. Scott Rowley, by his associate, Dr. Michele Donato, and by the entire transplantation team," says Andrew L. Pecora, M.D., chairman and executive administrative director of the John Theurer Cancer Center at Hackensack University Medical Center.

The Blood and Marrow Stem Cell Transplantation Program received Disease Specific Certification after a rigorous on-site, unannounced, day-long evaluation on August 29 that assessed clinical practices, policies and procedures, and performance measurement requirements. Four specific program measures were m
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The First Ever Transplantation World-Wide of Entire Arms at the "Klinikum rechts der Isar" in Munich
2. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
3. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
4. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. KGI Offers Mammalian Cell Culture Program for Biotech Industry Professionals
9. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
10. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
11. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
(Date:12/11/2009)... December 11, 2009 -- Esco announces the opening of a NEW ... as a technical service, training and logistics center to support Esco,s ... New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... opening of a NEW 2nd North American facility in Marietta, OH. ...
(Date:12/10/2009)... Institute (NEI), a division of the National Institutes of Health ... help fund its development of a non-invasive, passive diffusion-based treatment ... ... Salt Lake City, UT (PRWEB) December 10, 2009 ... National Institutes of Health (NIH), awarded a $2.18 million grant ...
(Date:12/10/2009)... of advanced flow measurement, control, and level solutions, ... as Global Level Product Manager effective November 30, ... enhance market penetration of the level measurement products ... from Lafarge Corp, a manufacturer of building materials, ... Sales. Bayda will report to Brooks Instrument Vice ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3
... (Nasdaq:,CPHD) today announced the appointment of leading ... Fred Tenover, Ph.D., as,Senior Director of Scientific ... liaison,with the Infection Control community and will ... "The objective of the Cepheid HAI ...
... 9 Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) ... 25mg meclizine HCl tablets immediately. At,this time, Par believes ... Par marketed meclizine prior to an explosion at ... has since qualified a new API source and,received the ...
... YARDLEY, Pa. and WOBURN, Mass., July 9 ... Business, Technology and,Regulatory strategies, and CBI Research Inc., ... executives in the pharmaceutical,and biotech industries, today announced ... will chair CBI,s "3rd Annual Manufacturing Execution,Systems for ...
Other Biology Technology:Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3Par Pharmaceutical to Launch meclizine HCL Tablets 2Axendia's President to Chair 3rd Annual MES for Life Sciences Congress 2
(Date:12/14/2009)... researchers from the Astrobiology Centre (INTA-CSIC) has shown that ... the formation of the most basic biological molecules can ... to carry out this study, published in the journal ... chemical conditions of the early Earth. , "We have ... solutions it produces hydrogen cyanide, a substance that could ...
(Date:12/14/2009)... WAYNE, Pa., Dec. 14 MODA Technology ... monitoring (EM), utility and product testing for the ... MODA 3.0, the company,s third generation mobile data ... (QC) organizations to further automate their regulated manufacturing ... new capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... Scientists have resolved a question about how a ... works using biosensors that reveal previously hidden components ... Although delusions and hallucinations characterize the illness, people ... recall information in a particular order, difficulties that ... or function well, said Lee Schroeder, a student ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 1Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 2Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 3Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 4Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory 62361 5Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 1Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 15027 3Neogen Acquires Gen Probes BioKits Food Safety Business 6639 1Neogen Acquires Gen Probes BioKits Food Safety Business 6639 2
... stand-in for humans in medical research, thanks to genomes ... behave differently in mouse and man, a study by ... Zhang reveals. , Their results, which have implications for ... appear in the current issue of the journal Proceedings ...
... Studying thousands of patients, Japanese researchers have found ... of three cancers esophageal, head and neck, and ... risk of developing these diseases. , In the May ... of the American Association for Cancer Research, scientists from ...
... bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a leading developer ... has filed 5 new patent applications with,the United ... covered by the filings include tool storage chests, ... The,traditional products that are the subject of the ...
Other Biology News:Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2bioMETRX, Inc. Files for Several New Patents 2